Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands. Proposed legislation that would make approved biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results